Mazella Estelle, Mendyk Anne-Marie, Accart Bertrand, Borsotto Marc, Heurteaux Catherine, Bordet Régis, Mazella Jean, Dondaine Thibaut
Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, UMR 7275, Université Côte d'Azur, 660, Route Des Lucioles, 06560 Valbonne, France.
University Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, Degenerative and Vascular Cognitive Disorders, Department of Pharmacology, Faculty of Medicine, 1, place de Verdun, 59045 Lille Cedex, France.
J Neurol Sci. 2025 May 15;472:123459. doi: 10.1016/j.jns.2025.123459. Epub 2025 Mar 8.
Post-stroke depression is a common and debilitating consequence of stroke that significantly impacts functional recovery and quality of life. Identifying new biological markers and treatments is essential to enhance patient care. This study aimed to assess the relationship between serum levels of the sortilin-derived propeptide and depression scores in the STROKDEM cohort (NCT01330160).
The study enrolled 204 stroke patients and followed them at 6, 12, 36, and 60 months post-stroke. Serum sortilin-derived propeptide levels were measured at each visit, along with comprehensive clinical assessments including depression and anxiety scales.
The results showed a significant main effect of serum sortilin-derived propeptide levels on depression scores (p = 0.006). There was also a significant interaction between propeptide levels and follow-up visit (p = 0.05). In contrast, propeptide levels did not have a significant effect on anxiety scores (p = 0.75).
These findings suggest serum sortilin-derived propeptide could be a useful biomarker for post-stroke depression. This opens up potential new treatment approaches, including the consideration of the drug spadin, which targets this peptide, for managing post-stroke depression in humans.
中风后抑郁是中风常见且使人衰弱的后果，会显著影响功能恢复和生活质量。识别新的生物标志物和治疗方法对于改善患者护理至关重要。本研究旨在评估STROKDEM队列（NCT01330160）中血清sortilin衍生前体肽水平与抑郁评分之间的关系。
该研究纳入了204名中风患者，并在中风后6个月、12个月、36个月和60个月对他们进行随访。每次随访时测量血清sortilin衍生前体肽水平，同时进行包括抑郁和焦虑量表在内的全面临床评估。
结果显示血清sortilin衍生前体肽水平对抑郁评分有显著的主效应（p = 0.006）。前体肽水平与随访之间也存在显著的交互作用（p = 0.05）。相比之下，前体肽水平对焦虑评分没有显著影响（p = 0.75）。
这些发现表明血清sortilin衍生前体肽可能是中风后抑郁的有用生物标志物。这开辟了潜在的新治疗方法，包括考虑使用针对该肽的药物spadin来治疗人类中风后抑郁。
